1311474-09-5

Basic information

• Product Name: N-{4-[(Cyclobutyloxy)amino]-3,4-dioxo-1-phenyl-2-butanyl}-2-(3-phenyl-1H-pyrazol-1-yl)nicotinamide
• CAS NO: 1311474-09-5
• Molecular Weight: 509.564
• Mol File: 1311474-09-5.mol

Chemical Properties

• CAS DataBase Reference: N-{4-[(Cyclobutyloxy)amino]-3,4-dioxo-1-phenyl-2-butanyl}-2-(3-phenyl-1H-pyrazol-1-yl)nicotinamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-{4-[(Cyclobutyloxy)amino]-3,4-dioxo-1-phenyl-2-butanyl}-2-(3-phenyl-1H-pyrazol-1-yl)nicotinamide(1311474-09-5)
• EPA Substance Registry System: N-{4-[(Cyclobutyloxy)amino]-3,4-dioxo-1-phenyl-2-butanyl}-2-(3-phenyl-1H-pyrazol-1-yl)nicotinamide(1311474-09-5)

Safety Data

• Hazardous Substances Data: 1311474-09-5(Hazardous Substances Data)

Upstream product

• 1037828-54-8 2-(3-phenyl-1H-pyrazol-1-yl)nicotinic acid 

Relevant articles and documents

Mitigating the Metabolic Liability of Carbonyl Reduction: Novel Calpain Inhibitors with P1′ Extension

Dysregulation of calpains 1 and 2 has been implicated in a variety of pathological disorders including ischemia/reperfusion injuries, kidney diseases, cataract formation, and neurodegenerative diseases such as Alzheimer's disease (AD). 2-(3-Phenyl-1H)-pyrazol-1-yl)nicotinamides represent a series of novel and potent calpain inhibitors with high selectivity and in vivo efficacy. However, carbonyl reduction leading to the formation of the inactive hydroxyamide was identified as major metabolic liability in monkey and human, a pathway not reflected by routine absorption, distribution, metabolism, and excretion (ADME) assays. Using cytosolic clearance as a tailored in vitro ADME assay coupled with in vitro hepatocyte metabolism enabled the identification of analogues with enhanced stability against carbonyl reduction. These efforts led to the identification of P1′ modified calpain inhibitors with significantly improved pharmacokinetic profile including P1′ N-methoxyamide 23 as potential candidate compound for non-central nervous system indications.

CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V

The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of